Investor directory

Meneldor

Meneldor is a biopharmaceutical investment company established in 2016 and located in Druten, Netherlands. The firm focuses on venture capital investments in early-stage biotechnology and pharmaceutical companies. Meneldor targets businesses that are involved in the redevelopment of new bio or chemical molecular entities and prioritize technologies with robust intellectual property. The company aims to support innovations that address substantial unmet medical needs in the healthcare sector.
http://meneldor.nl
https://crunchbase.com/organization/meneldor
https://linkedin.com/company/meneldor-b-v
https://pitchbook.com/profiles/investor/230427-73
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=597731782

Frans van Dalen

Co-Founding Partner

Paul Lelieveld

Founding Partner

4 past transactions

Hemispherian

Seed Round in 2022
Hemispherian is a biotechnology firm that formulates new treatments for all kinds of cancer.

Atriva Therapeutics

Debt Financing in 2020
Atriva Therapeutics is a biopharmaceutical company which aims to develop new antiviral therapies against different respiratory viral infections. Atriva Therapeutics completed preclinical development of ATR-002 and recently filed a request for scientific advice from a European regulatory authority to provide guidance on the executed preclinical development program and the planned ATR-002 Phase I study in healthy volunteers.

Atriva Therapeutics

Series A in 2019
Atriva Therapeutics is a biopharmaceutical company which aims to develop new antiviral therapies against different respiratory viral infections. Atriva Therapeutics completed preclinical development of ATR-002 and recently filed a request for scientific advice from a European regulatory authority to provide guidance on the executed preclinical development program and the planned ATR-002 Phase I study in healthy volunteers.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.